Myricx Bio to be Acquired by Novartis to Advance Next-Generation ADC Payloads for Oncology with Novel NMTi Platform
Potential first-in-class N-myristoyltransferase inhibitor (NMTi) ADC payload with a differ
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.